NCT06363760
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
Enrolling by Invitation
Not specifiedAges 12–50ObservationalEditas Medicine, Inc.
~54 participants
Updated 2025-04-02 on ClinicalTrials.gov
What's tested:Safety and efficacy assessments
At a glance
Recruiting sites
0 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events of special interest (AESI)
Measured over up to 15 years post EDIT-301 infusion
+4 more outcomes measured
Conditions
Where it's being run
18 sites across 14 statesNew York2
Ohio2
Texas2
Ontario2
California1
Colorado1
Connecticut1
Florida1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participant must have received an EDIT-301 infusion as part of a clinical study.
Participant or legal representative/guardian (if applicable) must sign and date the informed consent form (ICF) or assent, if applicable for this long-term follow-up study.
Exclusion
Participant is still actively enrolled in an EDIT-301 treatment study and has not yet met eligibility for long term follow-up in this study.
What this trial measures
- Adverse events of special interest (AESI)up to 15 years post EDIT-301 infusion
- Adverse events of interest (AEI)up to 15 years post EDIT-301 infusion
- All-cause mortalityup to 15 years post EDIT-301 infusion
- Adverse events (AEs) related to EDIT-301up to 15 years post EDIT-301 infusion
- Serious adverse events (SAEs)up to 15 years post EDIT-301 infusion